Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB5 days ago · OXBRYTA should not be taken if the patient has had an allergic reaction to voxelotor or any of the ingredients in OXBRYTA. See the end of the patient leaflet for a list of the ingredients in OXBRYTA.
FDA is alerting patients and health care professionals about the ...
WEB4 days ago · Pfizer Inc., the manufacturer of Oxbryta, announced it is voluntarily withdrawing the medication from the market, ceasing distribution, and discontinuing all active clinical trials and expanded ...
Pfizer withdraws sickle-cell disease treatment | Reuters
WEB5 days ago · Pfizer bought Oxbryta, also known as voxelotor, as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022. It reported $328 million in revenues from the therapy for the full year 2023.
Pfizer decision to withdrawal sickle cell drug leaves patients ...
WEB4 days ago · Sept. 26, 2024. Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and doctors, leaving many searching for answers and ...
FDA alerts patients about Pfizer's Oxbryta withdrawal
WEB4 days ago · Sept 26 (Reuters) - The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer's (PFE.N) sickle cell disease treatment Oxbryta ...
Pfizer pulls sickle cell pill Oxbryta over safety concerns - STAT
WEB4 days ago · Sept. 25, 2024. Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including ...
Pfizer pulls sickle cell disease therapy Oxbryta from markets
WEB4 days ago · Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 billion acquisition the New York pharma made two years ago.
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle ...
WEB4 days ago · Oxbryta was the centerpiece of Pfizer's $5.4 billion buyout of Global Blood Therapeutics in 2022, one of a number of deals bankrolled by the pandemic-era windfall. ... Reuters, the news and media ...
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB5 days ago · Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide.
Pfizer withdraws sickle cell treatment due to safety concerns
WEB3 days ago · Pfizer has voluntarily withdrawn its sickle cell disease treatment Oxbryta (voxelotor) from the market due to safety concerns. The Food and Drug Administration (FDA) recommends clinicians stop prescribing the treatment and patients talk to their doctor about starting a different treatment. “I am disappointed as many other providers, patients and families (are),” said Banu Aygun, M.D., FAAP ...